The Kislinger Laboratory is located at the Princess Margaret Cancer Research Tower of the Princess Margaret Cancer Centre, the largest oncology treatment and research facility in Canada. The major goal of our lab is to apply proteomics technologies to cancer and cardiovascular research. Our research interests include technology development, using the latest generation of mass spectrometry instrumentation, basic cell biology and translational cancer research.
Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Int J Cancer. 2016 Oct 17;:
Ectopic miR-125a Expression Induces Long-Term Repopulating Stem Cell Capacity in Mouse and Human Hematopoietic Progenitors.
Cell Stem Cell. 2016 Jul 12;
Development. 2016 Jul 1;143(13):e1.1
Nat Commun. 2016;7:11906
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Nat Cell Biol. 2016 Jun 20;
J Cell Sci. 2016 May 13;
Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
PLoS One. 2016;11(4):e0154074
Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.
Expert Rev Proteomics. 2016 Mar 12;
Clin Chem. 2016 Jan 27;
Senior Scientist, Princess Margaret Cancer Centre